Hubbry Logo
MelittinMelittinMain
Open search
Melittin
Community hub
Melittin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Melittin
Melittin
Melittin
View on Wikipedia
from Wikipedia
Melittin
Melittin
Identifiers
SymbolMelittin
PfamPF01372
InterProIPR002116
SCOP22mlt / SCOPe / SUPFAM
TCDB1.C.18
OPM superfamily151
OPM protein2mlt
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
Melittin[1]
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.157.496 Edit this at Wikidata
MeSH Melitten
UNII
  • InChI=1S/C131H229N39O31/c1-23-71(16)102(163-97(176)60-135)122(194)146-62-98(177)148-74(19)109(181)164-100(69(12)13)124(196)160-88(55-65(4)5)116(188)155-84(41-30-33-51-134)115(187)165-101(70(14)15)125(197)161-90(57-67(8)9)118(190)168-106(77(22)173)128(200)169-105(76(21)172)123(195)147-63-99(178)150-92(58-68(10)11)129(201)170-54-36-44-94(170)121(193)149-75(20)108(180)158-89(56-66(6)7)117(189)166-104(73(18)25-3)127(199)162-93(64-171)120(192)159-91(59-78-61-145-80-38-27-26-37-79(78)80)119(191)167-103(72(17)24-2)126(198)157-83(40-29-32-50-133)111(183)154-85(42-34-52-143-130(139)140)112(184)152-82(39-28-31-49-132)110(182)153-86(43-35-53-144-131(141)142)113(185)156-87(46-48-96(137)175)114(186)151-81(107(138)179)45-47-95(136)174/h26-27,37-38,61,65-77,81-94,100-106,145,171-173H,23-25,28-36,39-60,62-64,132-135H2,1-22H3,(H2,136,174)(H2,137,175)(H2,138,179)(H,146,194)(H,147,195)(H,148,177)(H,149,193)(H,150,178)(H,151,186)(H,152,184)(H,153,182)(H,154,183)(H,155,188)(H,156,185)(H,157,198)(H,158,180)(H,159,192)(H,160,196)(H,161,197)(H,162,199)(H,163,176)(H,164,181)(H,165,187)(H,166,189)(H,167,191)(H,168,190)(H,169,200)(H4,139,140,143)(H4,141,142,144)/t71-,72-,73-,74-,75-,76+,77+,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,100-,101-,102-,103-,104-,105-,106-/m0/s1 ☒N
    Key: VDXZNPDIRNWWCW-JFTDCZMZSA-N ☒N
  • InChI=1/C131H229N39O31/c1-23-71(16)102(163-97(176)60-135)122(194)146-62-98(177)148-74(19)109(181)164-100(69(12)13)124(196)160-88(55-65(4)5)116(188)155-84(41-30-33-51-134)115(187)165-101(70(14)15)125(197)161-90(57-67(8)9)118(190)168-106(77(22)173)128(200)169-105(76(21)172)123(195)147-63-99(178)150-92(58-68(10)11)129(201)170-54-36-44-94(170)121(193)149-75(20)108(180)158-89(56-66(6)7)117(189)166-104(73(18)25-3)127(199)162-93(64-171)120(192)159-91(59-78-61-145-80-38-27-26-37-79(78)80)119(191)167-103(72(17)24-2)126(198)157-83(40-29-32-50-133)111(183)154-85(42-34-52-143-130(139)140)112(184)152-82(39-28-31-49-132)110(182)153-86(43-35-53-144-131(141)142)113(185)156-87(46-48-96(137)175)114(186)151-81(107(138)179)45-47-95(136)174/h26-27,37-38,61,65-77,81-94,100-106,145,171-173H,23-25,28-36,39-60,62-64,132-135H2,1-22H3,(H2,136,174)(H2,137,175)(H2,138,179)(H,146,194)(H,147,195)(H,148,177)(H,149,193)(H,150,178)(H,151,186)(H,152,184)(H,153,182)(H,154,183)(H,155,188)(H,156,185)(H,157,198)(H,158,180)(H,159,192)(H,160,196)(H,161,197)(H,162,199)(H,163,176)(H,164,181)(H,165,187)(H,166,189)(H,167,191)(H,168,190)(H,169,200)(H4,139,140,143)(H4,141,142,144)/t71-,72-,73-,74-,75-,76+,77+,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,100-,101-,102-,103-,104-,105-,106-/m0/s1
    Key: VDXZNPDIRNWWCW-JFTDCZMZBB
  • CCC(C)C(C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(Cc2c[nH]c3c2cccc3)C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)N)NC(=O)CN
Properties
C131H229N39O31
Molar mass 2846.46266
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Melittin is the main component (40–60% of the dry weight) and the major pain-producing substance of honeybee (Apis mellifera) venom. Melittin is a basic peptide consisting of 26 amino acids.[2]

Function

[edit]

The principal function of melittin as a component of bee venom is to cause pain and destruction of tissue of intruders that threaten a beehive.[citation needed] However, melittin is expressed, not only in the venom gland, but also in other tissues when the bee is infected with various pathogens.[citation needed] The over-expression of melittin (as well as secapin, another venom molecule) in infected honey bees may indicate that it plays a role in the immune response of bees to infectious diseases.[3]

Structure

[edit]

Melittin is a small peptide with no disulfide bridge; the N-terminal part of the molecule is predominantly hydrophobic and the C-terminal part is hydrophilic and strongly basic. In water, it forms a tetramer, but it also can spontaneously integrate itself into cell membranes.[4]

Mechanism of action

[edit]

Injection of melittin into animals and humans causes pain sensations. It has strong surface effects on cell membranes, causing pore formation in epithelial cells and the destruction of red blood cells. Melittin also activates nociceptor (pain receptor) cells through a variety of mechanisms.[2]

Melittin can open thermal nociceptor TRPV1 channels via cyclooxygenase metabolites, resulting in depolarization of nociceptor cells. The pore-forming effects in cells cause the release of pro-inflammatory cytokines. It also activates G-protein-coupled receptor-mediated opening of transient receptor potential channels. Finally, melittin up-regulates the expression of Nav1.8 and Nav1.9 sodium channels in nociceptor cell, causing long-term action-potential firing and pain sensation.[2]

Melittin inhibits protein kinase C, Ca2+/calmodulin-dependent protein kinase II, myosin light chain kinase, and Na+/K+-ATPase (synaptosomal membrane). Melittin blocks transport pumps such as the Na+-K+-ATPase and the H+-K+-ATPase.[2]

Toxicity of a bee sting

[edit]
See also: Bee sting

Melittin is the main compound in bee venom, accounting for its potential lethality, caused by an anaphylactic reaction in some people.[5] At the sites of multiple stings, localized pain, swelling, and skin redness occur, and if bees are swallowed, life-threatening swelling of the throat and respiratory passages may develop.[5]

Use

[edit]

Bee venom therapy has been used in traditional medicine for treating various disorders,[6] although its non-specific toxicity has limited scientific research on its potential effects.[7]

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Melittin

View on Grokipedia
from Grokipedia
Melittin is a linear, cationic, amphipathic peptide consisting of 26 amino acids (sequence: GIGAVLKVLTTGLPALISWIKRKRQQ), with a molecular weight of approximately 2846 Da and a net positive charge of +6 at physiological pH, making it the major bioactive component of honey bee (Apis mellifera) venom, where it accounts for 50–60% of the dry weight. This water-soluble peptide, with a hydrophobic N-terminal region and hydrophilic C-terminal region, is synthesized in the bee's venom gland and plays a central role in the venom's defensive and predatory functions by disrupting target cell membranes. Renowned for its cytolytic properties, melittin exerts broad biological effects through a non-selective mechanism involving the insertion into lipid bilayers to form toroidal pores, which cause ion leakage, permeabilization, and subsequent cell lysis or . This action underpins its activity against , fungi, and parasites, as well as its hemolytic and pain-inducing effects, the latter contributing significantly to the sting's nociceptive response via activation of pain receptors like TRPV1. Additionally, melittin demonstrates effects by inhibiting pathways such as and toll-like receptors, while its antiviral properties have been observed in preclinical models. In therapeutic contexts, melittin has garnered attention for its anticancer potential, inducing tumor across various malignancies, including , , and hepatocellular carcinomas, through mitochondrial disruption and suppression of proliferation signals like Rac1. However, its non-specific toxicity, particularly , limits direct clinical use, prompting research into delivery systems such as nanoparticles or conjugates to enhance selectivity and efficacy. Emerging studies also explore its neuroprotective and antinociceptive roles, such as alleviating chemotherapy-induced neuropathy, highlighting its multifaceted pharmacological profile.

Discovery and Biosynthesis

Historical Discovery

Melittin was first identified as a key hemolytic component of honey in 1953 by Werner Neumann and Erich Habermann, who isolated it through studies and demonstrated its ability to lyse erythrocytes by disrupting cell membranes. Their work, published in Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie, marked the initial recognition of melittin as a potent lytic factor responsible for much of the venom's toxic effects. This discovery built on earlier explorations of 's pharmacological properties in the early 1950s, including improved venom collection techniques developed in around 1960, which facilitated larger-scale isolation efforts. During the 1950s and 1960s, researchers conducted extensive of honeybee (Apis mellifera) , confirming melittin as the predominant toxic , comprising approximately 40-60% of the dry weight. Early toxicological studies highlighted its role in inducing and membrane damage, with Habermann and colleagues further purifying it and elucidating its through tryptic and peptic degradation in 1967, revealing a 26-amino-acid sequence. These investigations positioned melittin as the major contributor to the 's pain-inducing effects, eliciting intense, tonic pain and in animal models due to its direct activation of nociceptors. By the early 1970s, bee venom research in and had advanced significantly, with Erich Habermann's comprehensive 1972 review synthesizing decades of findings on melittin's lytic properties and its with other venom components like A2. This period emphasized melittin's amphiphilic nature as central to its membrane-disrupting activity, informing early understandings of venom as a model for studying cellular and . Such studies laid the groundwork for recognizing melittin not only as a defensive but also as a pharmacologically active agent in experimental contexts.

Biosynthesis in Honeybees

Melittin is synthesized in the venom gland secretory cells and cells of the honeybee Apis mellifera as a 70-residue preproprotein, featuring an N-terminal that directs it to the for processing. This precursor form ensures proper localization and maturation within these tissues, where it undergoes posttranslational modifications essential for its bioactivity. The proceeds through sequential proteolytic cleavages: the is first removed to yield a proprotein, which is further processed by dipeptidylpeptidase IV into a 50-residue promelittin intermediate consisting of an N-terminal pro-sequence and the C-terminal melittin domain. The promelittin is then cleaved to release the mature 26-residue melittin, with the C-terminal glutamine-glycine converted to a glutamine-amide via enzymatic amidation, enhancing its amphipathic properties and stability. These steps occur primarily in the post-Golgi secretory pathway of venom gland cells. Gene expression of the melittin precursor is regulated during honeybee development, peaking in the first week of adult worker life, where it correlates with venom maturation and accumulation. This expression is largely restricted to workers, reflecting their role in colony defense, though recent findings indicate upregulation in cells during bacterial infections such as those by and , suggesting an additional function beyond production. Recent studies as of 2024 confirm this production, highlighting melittin's role in systemic immune defense. Evolutionarily, melittin originated from ancestral peptide hormones approximately 190 million years ago in aculeate hymenopterans, with divergence in bees around 130 million years ago and further specialization in honeybees about 30 million years ago, adapting its structure for membrane-disrupting activity while retaining hormonal sequence motifs. In venom, mature melittin constitutes up to 50% of the dry weight, underscoring its biosynthesis as a key contributor to the overall toxicity profile.

Chemical Structure

Amino Acid Sequence

Melittin is a 26-amino acid polypeptide with the primary sequence Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln (GIGAVLKVLTTGLPALISWIKRKRQQ), originally determined through tryptic and peptic degradation analysis. Its molecular formula is C₁₃₁H₂₂₉N₃₉O₃₁, corresponding to a molecular weight of approximately 2846 Da. The sequence exhibits an amphiphilic character, featuring a predominantly hydrophobic N-terminal region spanning the first 20 residues (primarily composed of nonpolar such as , , , , and ) and a hydrophilic C-terminal region enriched with positively charged and residues. This distribution of hydrophobic and cationic residues contributes to its membrane-interacting properties. Melittin undergoes post-translational C-terminal amidation, converting the glutamine residue to a (-NH₂), which is essential for enhancing its , including disruption and efficacy. Related peptides in other venoms, such as mastoparans from vespid wasps (e.g., Mastoparan-X: INLKALAALAKKIL-NH₂), share functional and structural similarities with melittin as amphipathic, cationic α-helical toxins but display low sequence identity, typically below 20%, while preserving key features like hydrophobic faces and basic C-termini.

Conformation and Properties

Melittin predominantly adopts an α-helical conformation in membrane-mimetic environments, such as bilayers, where (CD) spectroscopy indicates helical contents ranging from 70% to over 80%, depending on the composition. In aqueous solutions, however, melittin exists primarily in a or partially unstructured state at low concentrations, transitioning to oligomeric forms that exhibit partial helicity. The amphipathic nature of this helix, with a hydrophobic face comprising nonpolar residues and a hydrophilic face rich in basic , is evident from (NMR) and X-ray crystallographic studies, which reveal a bent rod-like structure with a hinge at the Pro14-Gly12 region. In solution, melittin forms tetramers or higher oligomers at physiological concentrations and in the presence of salts, stabilizing the structure by burying hydrophobic surfaces and enhancing solubility. Upon interaction with membranes, it dissociates into monomers that insert as α-helices, as confirmed by solid-state NMR showing monomeric embedding in lipid environments like DTPC bilayers. This oligomeric-to-monomeric transition underscores melittin's adaptability to different milieus. Melittin's physicochemical properties reflect its amphipathic composition: it is highly soluble in aqueous solutions (up to millimolar concentrations) as a tetramer but denatures into unstructured monomers at very low concentrations or in without salts. It remains stable in nonpolar solvents like , where it forms a continuous α-helix, as observed in solution NMR spectra. The (pI) is approximately 12, attributed to its six positively charged residues (five basic and one N-terminal ), conferring a net positive charge at physiological . This basicity, combined with the hydrophobic core, facilitates its membrane partitioning while maintaining solubility in polar media.

Biological Role

Composition in Bee Venom

Melittin constitutes 40–60% of the dry weight of venom from the honeybee Apis mellifera, rendering it the predominant peptide component. This venom also contains other key bioactive molecules, including (approximately 10–12% of dry weight), (1–3%), and apamin (2–3%), which collectively contribute to the venom's pharmacological profile. These proportions can vary slightly based on environmental factors and bee age, but melittin remains the major constituent across samples. Melittin exhibits synergistic interactions with other venom components, particularly enhancing the activity of . This cooperation facilitates greater membrane permeabilization and subsequent tissue damage by allowing to more effectively hydrolyze phospholipids in target cell membranes. Such synergies amplify the overall lytic potency of the venom beyond what either component achieves alone. Concentrations of melittin in bee venom display variations across species and castes. For instance, one study reported melittin comprising 95.8% in Apis dorsata (giant honeybee) and 76.5% in Apis mellifera of the venom's peptide content by dry weight, though standard values for Apis mellifera are 40–60% of total dry weight. Extraction of melittin from whole bee venom typically begins with collection via low-voltage electrical stimulation of live worker bees, yielding crude venom that is lyophilized for storage. Purification methods include strong cation-exchange chromatography at pH 6.0 using sodium phosphate buffer, which isolates melittin with high recovery (over 90%), or reverse-phase (HPLC) on octadecylsilica (ODS) columns with stepwise gradients for further refinement. These techniques ensure removal of contaminants like while preserving melittin's bioactivity.

Defensive Function

Melittin functions primarily as a defensive agent in honeybee , inducing severe and in predators by lysing cell membranes, which effectively deters threats to the such as , reptiles, mammals, and birds. This cytotoxic action disrupts target tissues, immobilizing small invaders and discouraging larger ones from approaching the hive. In the sting apparatus, melittin is released during , triggering rapid local that enhances the bee's ability to repel attackers and protect the nest. Its abundance in venom, accounting for 40–50% of the dry weight, allows even minute quantities delivered by a single sting to produce potent effects. Evolutionarily, melittin's high concentration has been refined over approximately 90 million years to ensure lethality in small doses against diverse predators, including and small mammals, through conservative substitutions across Apis species. This underscores its role in survival by maximizing defensive efficacy with minimal expenditure. Beyond direct antipredator defense, melittin contributes to hive via its properties, acting as a social on adult cuticles and to inhibit bacterial, fungal, and viral pathogens. This secondary function supports collective immunity, reducing infection risks in the humid colony environment across species like Apis mellifera and .

Mechanism of Action

Membrane Interaction

Melittin initiates membrane disruption through electrostatic interactions between its positively charged C-terminal region and anionic phospholipids, such as or phosphatidylglycerol, in the , which facilitates initial binding at the membrane-water interface. This binding is followed by the hydrophobic insertion of the peptide's N-terminal amphipathic α-helix into the acyl chain region of the bilayer, driven by the partitioning of its hydrophobic residues and leading to local membrane destabilization. The amphipathic nature of melittin, with its helical conformation, positions one face toward the hydrophobic core while the other interacts with polar headgroups, promoting deeper embedding. Several models describe melittin's pore-forming action on membranes. In the toroidal pore model, 4-8 melittin monomers aggregate to form a ring-like structure where lipid headgroups line the pore walls, bending the bilayer inward and creating a continuous channel approximately 4-4.5 nm in diameter. Alternatively, the carpet mechanism involves high-density coverage on the surface, acting detergent-like to solubilize and fragment the bilayer without discrete pores. A third model proposes line defects, where melittin induces ordered disruptions or packing defects in the lipid array, facilitating transient leakage without full pore formation. Melittin's membrane-disrupting behavior is concentration-dependent, with monomeric forms predominating at low peptide-to-lipid (P/L) ratios (e.g., <1:200), causing transient permeabilization through shallow insertion and reversible defects; recent studies confirm these as stochastically dissolving toroidal pores involving 6-12 peptides with fluctuating diameters of 2-4 nm, driven by transbilayer asymmetry rather than stable equilibrium structures. At higher concentrations (P/L ≥1:20), melittin oligomerizes into stable aggregates, transitioning to persistent toroidal pores or carpet-like lysis, which amplifies membrane leakage. Experimental evidence for these interactions includes fluorescence quenching assays, where tryptophan residues in melittin quench nearby fluorophores upon insertion, confirming binding and oligomerization depths in the bilayer. Calcein release assays from entrapped vesicles demonstrate pore-mediated leakage, with release kinetics indicating pore sizes of approximately 1-2.5 nm that scale with P/L ratio, supporting toroidal models over smaller barrel-stave structures.

Intracellular Effects

Upon membrane disruption by melittin, which forms pores allowing non-selective passage, there is rapid leakage of intracellular ions such as and , along with metabolites, leading to osmotic imbalance and subsequent cell lysis. This efflux of has been shown to activate the NLRP3 inflammasome in certain immune cells, while the influx of elevates intracellular concentrations, disrupting homeostasis and promoting necrotic cell death in susceptible populations. The resulting osmotic swelling and rupture exemplify as a primary outcome in non-apoptotic pathways. Melittin further amplifies intracellular signaling by activating phospholipases, particularly phospholipase A2 (PLA2), which hydrolyzes membrane phospholipids to release arachidonic acid and other fatty acids. This liberation of arachidonic acid serves as a precursor for eicosanoid synthesis, triggering inflammatory cascades via cyclooxygenase and lipoxygenase pathways. Such activation contributes to downstream pro-inflammatory effects, including enhanced cytokine production and immune cell recruitment. In addition to plasma membrane effects, melittin targets mitochondrial membranes in a context-dependent manner, causing depolarization of the mitochondrial membrane potential and release of cytochrome c, which initiates the intrinsic apoptotic pathway in cancer cells; however, in normal cells, it can exhibit cytoprotective effects by preserving membrane integrity, reducing reactive oxygen species (ROS), and regulating mitophagy through pathways such as PINK1/Parkin and AMPK. This interference elevates ROS production and activates caspases, such as caspase-3, leading to programmed cell death rather than necrosis in nucleated cells capable of apoptotic responses. The intracellular impacts of melittin exhibit species- and cell-type specificity, with pronounced hemolysis in erythrocytes due to their anucleate nature and high susceptibility to osmotic lysis from ion leakage. In contrast, nucleated cells often display variable responses, showing reduced toxicity and a shift toward apoptosis over necrosis, as seen in peripheral blood mononuclear cells compared to enucleated red blood cells.

Toxicity

Pathophysiological Impacts

Melittin, the primary toxic component of bee venom, induces acute pathophysiological effects primarily through its membrane-disrupting properties, leading to hemolysis, hypotension, and anaphylaxis in exposed individuals. Hemolysis arises from melittin's ability to form pores in erythrocyte membranes, causing red blood cell lysis and subsequent release of hemoglobin, which can contribute to renal damage if severe. Hypotension results from increased vascular permeability and systemic inflammatory responses triggered by melittin, often exacerbating shock in envenomations. Anaphylaxis, an IgE-mediated hypersensitivity reaction, occurs in sensitized humans, manifesting as bronchoconstriction, urticaria, and cardiovascular collapse, particularly following multiple stings. In mice, the intravenous LD50 for melittin is approximately 3–4 mg/kg, reflecting its high potency in systemic administration. In humans, severe reactions, including potentially lethal outcomes, have been reported from 200–500 stings, delivering an estimated total melittin dose of 10–25 mg (roughly 140–360 μg/kg for a 70 kg adult), though allergic individuals may react severely to far lower exposures. Survivors of massive envenomation may develop long-term sequelae such as chronic kidney disease in rare cases. In therapeutic contexts like bee venom therapy (apitherapy), low-dose repeated exposures are generally safe but carry risks of anaphylaxis and rare local reactions; systematic reviews report adverse events in about 29% of cases, mostly mild. Acute neurotoxic effects include persistent hyperalgesia and allodynia due to melittin's activation of nociceptors via G protein-coupled receptors and TRPV1 channels, lasting up to 96 hours post-envenomation. Neurological complications such as Guillain-Barré syndrome have been reported in rare cases of massive stings. The dose-response relationship of melittin exhibits a biphasic pattern: low doses (e.g., from single stings, ~0.05 mg melittin) primarily elicit localized pain and inflammation through cytokine release and edema. High doses (e.g., >10 mg total, from numerous stings) provoke systemic toxicity, culminating in multi-organ failure involving cardiovascular collapse, , and hepatic dysfunction. Severity of melittin-induced impacts is modulated by factors such as pre-existing allergies, which heighten anaphylactic , and age or comorbidities that impair physiological compensation. species variations also influence outcomes; for instance, Africanized honeybees deliver lower melittin per sting but compensate through aggressive swarming, resulting in higher cumulative doses compared to European honeybees.

Role in Bee Stings

Melittin plays a central role in the acute effects of during a single sting, where approximately 50–140 μg of honeybee is injected, with melittin comprising 40–60% of this amount, or roughly 20–84 μg. This induces immediate, intense by activating nociceptors through transient receptor potential vanilloid 1 () channels and upregulating voltage-gated sodium channels Nav1.8 and Nav1.9, resulting in tonic pain sensations rated above 8 on a 0–10 scale. Additionally, melittin promotes local via rapid inflammatory responses that peak within 10–20 minutes, driven by its pore-forming action on cell membranes. In cases of multiple stings, the cumulative venom dose—often exceeding several hundred micrograms—amplifies melittin's toxicity, leading to systemic complications such as , characterized by elevated levels up to 58,000 IU/L, and subsequent acute renal failure due to direct and . These effects can progress to multi-organ failure and prove fatal, particularly in individuals with , where even moderate may trigger lethal anaphylactic shock. Melittin's hemolytic properties exacerbate renal injury by causing intravascular and tubular damage. Melittin interacts with the by inducing through membrane pore formation, thereby releasing and other mediators that initiate reactions, manifesting as urticaria, , and within minutes of . This IgE-mediated response heightens the risk of in sensitized individuals. Treatment for focuses on mitigating melittin-induced effects: intramuscular epinephrine serves as the first-line intervention for to counteract , while supportive measures such as aggressive intravenous hydration, diuretics, and address and renal failure in severe multi-sting cases.

Therapeutic Applications

Anticancer Potential

Melittin demonstrates selective against cancer cells, primarily due to their enriched content of anionic phospholipids, such as , exposed on the outer membrane leaflet, which enhances the peptide's amphipathic binding and pore-forming activity compared to normal cells with more zwitterionic lipids. This targeted membrane disruption triggers through mitochondrial pathways, including depolarization of the mitochondrial membrane potential, release, generation, and subsequent activation. In vitro studies have consistently shown melittin's inhibition of across multiple cancer types, including (e.g., MDA-MB-231 and lines), (e.g., A549 and NCI-H460), and prostate (e.g., PC-3 and ) cancers, often achieving values in the low micromolar range via induction and arrest. In vivo evidence from xenograft mouse models further supports these effects, with melittin reducing tumor growth and in and cancers by suppressing and markers like VEGF and MMP-9. A 2025 study demonstrated that melittin inhibits non-small cell (NSCLC) by targeting USP10 and promoting RNF20-mediated ubiquitination and degradation. Additionally, melittin synergizes with chemotherapeutic agents such as , enhancing their uptake and efficacy while overcoming multidrug resistance in resistant tumor cells. A major challenge in melittin's therapeutic use is its non-specific hemolytic and cytotoxic effects on healthy tissues, prompting the development of targeted delivery systems like encapsulation to improve specificity and reduce systemic toxicity. Recent 2025 studies have highlighted poly(lactic-co-glycolic acid) () nanoparticles loaded with melittin, which demonstrate enhanced stability, prolonged circulation, and alleviated in animal models while preserving antitumor activity. As of November 2025, no melittin-based drugs have been approved for anticancer treatment, with research largely confined to preclinical stages.

Antimicrobial and Anti-inflammatory Uses

Melittin exhibits broad-spectrum activity primarily through disruption of microbial cell membranes, forming pores that lead to leakage of cellular contents and . This mechanism is effective against both Gram-positive and , as well as fungi, including drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and Candida species. Representative minimum inhibitory concentrations (MICs) range from approximately 1-10 μg/mL for bacteria such as MRSA, while for Candida species, MICs are higher, typically 4-32 μM (approximately 11-91 μg/mL). In addition to its direct action, melittin displays significant properties by modulating key signaling pathways, notably inhibiting the pathway through direct binding to the p50 subunit and suppression of activity. This leads to reduced production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, as well as decreased expression of enzymes like COX-2 and iNOS. In preclinical models of , such as collagen-induced arthritis in rats, melittin administration has been shown to alleviate joint swelling, inhibit synovial fibroblast proliferation, and suppress cytokine-driven inflammation without excessive toxicity. To improve selectivity and reduce off-target effects on mammalian cells, researchers have developed modified forms of melittin, including N-terminal conjugates that enhance potency while minimizing hemolytic activity. For instance, these variants exhibit improved MICs against and compared to native melittin, with reduced in eukaryotic models. Preclinical studies further support melittin's therapeutic potential in infection-related . In models, such as diabetic rat excisional wounds, topical melittin formulations promote tissue repair by reducing bacterial load (e.g., against ), enhancing deposition, and attenuating local . Similarly, in sepsis models induced by (LPS), systemic melittin administration lowers storms, improves survival rates, and mitigates organ damage, such as , through inhibition and attenuation.

Research Developments

Preclinical and Clinical Studies

Preclinical studies have demonstrated melittin's efficacy in animal models for , particularly through tumor regression in mice. In mouse models, melittin-loaded nanoparticles significantly reduced tumor growth by targeting tumor cells while minimizing off-target effects. Similarly, in Lewis lung mouse models, melittin administration inhibited rapid tumor progression compared to controls, highlighting its potential in suppressing tumor-associated activity. For applications, melittin has shown robust disruption in preclinical assays against multidrug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), where it penetrated and degraded matrices, often synergistically with antibiotics like to enhance eradication without notable at effective doses. Recent nanoparticle formulations, including melittin-encapsulated polymeric systems up to 2025, have further improved delivery, extending circulation time and enabling targeted inhibition in in vivo models. Clinical trials involving melittin, primarily through (bee venom therapy containing melittin), have been conducted in Phase I/II for conditions like pain and (MS). A randomized crossover trial in relapsing-remitting MS patients found that bee venom injections did not significantly reduce disease activity, , or fatigue compared to , though it was generally well-tolerated. has also shown preliminary benefits in for chronic inflammatory conditions, with Phase II studies indicating reduced symptom severity in and cohorts. A 2024 randomized controlled trial on bee venom phonophoresis for mild to moderate localized plaque reported potential improvements in skin inflammation. However, data on purified melittin remain limited due to its inherent , including and rapid systemic clearance. Pharmacokinetic profiles of melittin reveal rapid clearance from plasma, with a distribution of approximately 0.8 minutes and an elimination of about 24 minutes following intravenous administration, necessitating advanced delivery systems to mitigate this. Formulation advances, such as encapsulation, have extended melittin's beyond 300 minutes in preclinical models while reducing hemolytic toxicity and enhancing tumor accumulation. Regulatory status as of 2025 positions melittin-based therapies as investigational in the and ; bee venom derivatives like Apitox have completed Phase 3 trials for pain and are pending FDA approval, advancing toward potential market entry despite ongoing toxicity challenges.

Challenges and Future Directions

Despite its promising therapeutic potential, melittin faces significant challenges in clinical translation, primarily due to its high hemolytic toxicity, which causes at concentrations effective against cancer cells. This non-specific membrane disruption limits and increases the risk of adverse effects. Additionally, melittin exhibits poor stability, undergoing rapid enzymatic degradation in plasma, which shortens its and reduces efficacy. Delivery challenges further complicate its use, as poor hinder targeted accumulation at tumor sites while promoting off-target distribution. Immunogenicity poses another barrier, particularly with repeated dosing, where anti-drug antibodies can accelerate clearance and diminish therapeutic responses. To address these limitations, researchers have developed engineered variants of melittin, including polyphenol-melittin complexes reported in 2025 that induce oligomerization to sequester toxic monomers, thereby reducing and hemolytic activity. Other modifications, like substitutions, further mitigate by evading immune recognition during repeated administrations. Looking ahead, future directions in melittin research emphasize AI-designed analogs to optimize selectivity and reduce through predictive modeling of peptide-membrane interactions. Combination therapies, such as melittin paired with EGFR inhibitors like , show synergistic anticancer effects by enhancing while minimizing individual doses to curb side effects. Gene therapy approaches enabling targeted melittin expression under tumor-specific promoters, like TERT, offer a pathway for localized delivery and avoidance of systemic . Ethical and regulatory considerations also shape melittin's development, including the need for sustainable harvesting practices from managed hives to meet growing demand. As of 2025, of sourcing remains critical to ensure consistent composition and purity, addressing inconsistencies in extraction methods that affect reproducibility across studies.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC7693387/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC5682937/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC5563768/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC10385528/
  5. https://pubmed.ncbi.nlm.nih.gov/33796975/
  6. https://pubmed.ncbi.nlm.nih.gov/40038194/
  7. https://pubmed.ncbi.nlm.nih.gov/13072631/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC9965945/
  9. https://www.science.org/doi/10.1126/science.177.4046.314
  10. https://pubmed.ncbi.nlm.nih.gov/5592400/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC7072249/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC9235364/
  13. https://doi.org/10.1111/j.1432-1033.1980.tb06073.x
  14. https://hal.science/hal-00892163/document
  15. https://doi.org/10.1016/j.cbpc.2024.109928
  16. https://pubchem.ncbi.nlm.nih.gov/compound/Melittin
  17. https://pubs.acs.org/doi/10.1021/jacs.2c12631
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC4796345/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC4417959/
  20. https://www.sciencedirect.com/science/article/pii/S2590171022000297
  21. https://pubs.acs.org/doi/10.1021/jp056124l
  22. https://www.nature.com/articles/s41598-025-91951-8
  23. https://www.sciencedirect.com/science/article/pii/S0006349501759188
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC1301742/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC6333091/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC8698802/
  27. https://www.sciencedirect.com/topics/chemistry/melittin
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC7998195/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC6743376/
  30. https://www.mdpi.com/2072-6651/16/3/117
  31. https://www.cell.com/biophysj/pdfExtended/S0006-3495%2822%2900229-6
  32. https://febs.onlinelibrary.wiley.com/doi/pdf/10.1016/0014-5793%252895%252900964-B
  33. https://pubmed.ncbi.nlm.nih.gov/27666985/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC5845530/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC4626175/
  36. https://www.sciencedirect.com/science/article/abs/pii/S004101011100273X
  37. https://pubmed.ncbi.nlm.nih.gov/10961508/
  38. https://doi.org/10.1016/S0006-3495(01)75802-6
  39. https://pubmed.ncbi.nlm.nih.gov/11509361/
  40. https://www.pnas.org/doi/10.1073/pnas.1307010110
  41. https://pubmed.ncbi.nlm.nih.gov/29401422/
  42. https://www.nature.com/articles/s41467-024-51691-1
  43. https://doi.org/10.1016/j.bpj.2018.05.006
  44. https://pubmed.ncbi.nlm.nih.gov/9251799/
  45. https://doi.org/10.1016/S0006-3495(97)78115-3
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC5596576/
  47. https://www.sciencedirect.com/science/article/pii/S0006349522002296
  48. https://pubmed.ncbi.nlm.nih.gov/1851918/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC3125126/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC11001274/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC4789993/
  52. https://doi.org/10.1016/j.toxicon.2025.108555
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC6273919/
  54. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.02090/full
  55. https://www.sciencedirect.com/science/article/abs/pii/S0196064499704282
  56. https://www.jci.org/articles/view/38842
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC5459532/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC4440710/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC11445026/
  60. https://pubmed.ncbi.nlm.nih.gov/2200291/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC10975291/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC3632030/
  63. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1628014/full
  64. https://www.mdpi.com/1422-0067/21/3/746
  65. https://www.mdpi.com/2072-6643/15/14/3111
  66. https://www.nature.com/articles/s41698-020-00129-0
  67. https://www.oncotarget.com/article/18627/text/
  68. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-06903-7
  69. https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-023-02223-4
  70. https://www.mdpi.com/1999-4923/17/8/1019
  71. https://link.springer.com/article/10.1007/s00432-023-05458-8
  72. https://www.sciencedirect.com/science/article/abs/pii/S1773224725005040
  73. https://www.researchgate.net/publication/395329826_PLGA_nanoparticles_provide_a_safe_delivery_system_for_bee_venom_and_melittin_to_alleviate_their_hepatotoxic_effects_in_mice
  74. https://pubmed.ncbi.nlm.nih.gov/40921336/
  75. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
  76. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1030401/full
  77. https://www.sciencedirect.com/science/article/pii/S2950194625003437
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC10838977/
  79. https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-021-00503-z
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC11695321/
  81. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1326033/full
  82. https://doi.org/10.1002/art.20626
  83. https://www.mdpi.com/1422-0067/25/2/867
  84. https://doi.org/10.1080/10717544.2022.2086943
  85. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.01348/full
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC10763831/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC5589633/
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC10870424/
  89. https://pubmed.ncbi.nlm.nih.gov/16221950/
  90. https://www.researchgate.net/publication/386146368_Bee_Venom_Phonophoresis_on_Mild_to_Moderate_Localized_Plaque_Psoriasis_on_a_Knee_Joint_a_Randomized_Controlled_Trial
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC2735896/
  92. https://www.mdpi.com/2218-273X/12/1/118
  93. https://xtalks.com/apimeds-pharmaceuticals-us-ipo-backs-bee-venom-for-osteoarthritis-treatment-4251/
  94. https://pubs.acs.org/doi/10.1021/acsami.5c09472
  95. https://www.futuremarketinsights.com/reports/bee-venom-extract-market
Add your contribution
Related Hubs
User Avatar
No comments yet.